Position in CYTK
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,029,861
-$95,749 QoQ
Shares Held
12,089
-29.2% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#261
of 477 holders
Holding Since
Mar 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Amundi holds $2,427,056,148 across 70 Biotechnology names. CYTK ranks #26 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,546,509 | $768,197,412 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,013,540 | $631,982,729 | |
| 3 | RPRX |
Royalty Pharma plc
|
3,723,864 | $208,797,052 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
617,471 | $185,877,294 | |
| 5 | INCY |
Incyte Corp
|
1,181,498 | $133,934,612 | |
| 6 | TECH |
BIO-TECHNE Corp
|
1,827,241 | $129,094,576 | |
| 7 | MRNA |
Moderna, Inc.
|
888,779 | $62,241,193 | |
| 8 | ARGX |
Argenx SE
|
65,122 | $60,418,237 |
All Filings in CYTK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,029,861 | 12,089 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $1,125,610 | 17,078 | Shares | Defined | 2026-05-18 | |
| 2025-12-31 | $430,356 | 6,773 | Shares | Defined | 2026-02-17 | |
| 2025-03-31 | $2,170 | 54 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $2,493 | 53 | Shares | Defined | 2025-02-07 | |
| 2023-12-31 | $1,099,396 | 13,168 | Shares | Defined | 2024-02-14 | |
| 2023-09-30 | $354,344 | 12,028 | Shares | Defined | 2023-11-14 | |
| 2023-06-30 | $400,280 | 12,271 | Shares | Defined | 2023-08-14 | |
| 2023-03-31 | $456,484 | 12,972 | Shares | Defined | 2023-05-15 | |
| No filing history on record for this holder in this stock. | ||||||